Details for Patent: 10,603,314

Which drugs does patent 10,603,314 protect, and when does it expire?

Patent 10,603,314 protects VIZIMPRO and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 10,603,314

Title:	Method for treating gefitinib resistant cancer
Abstract:	The present invention is directed to methods for the treatment of gefitinib and/or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and/or erlotinib. Progression of the cancer is indicative that the cancer is resistant to gefitinib and/or erlotinib. Once progression of cancer is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357.
Inventor(s):	Haber; Daniel A. (Chestnut Hill, MA), Bell; Daphne Winifred (Chevy Chase, MD), Settleman; Jeffrey E. (Newton, MA), Sordella; Raffaella (Cold Spring Harbor, NY), Godin-Heymann; Nadia G. (Stanmore, GB), Kwak; Eunice L. (Marlborough, MA), Rabindran; Sridhar Krishna (Eagleville, PA)
Assignee:	The General Hospital Corporation (Boston, MA) Wyeth LLC (New York, NY)
Application Number:	11/883,474
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,603,314

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-001	Sep 27, 2018		RX	Yes	No						ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-002	Sep 27, 2018		RX	Yes	No						ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
Pfizer	VIZIMPRO	dacomitinib	TABLET;ORAL	211288-003	Sep 27, 2018		RX	Yes	Yes						ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION

Foreign Priority and PCT Information for Patent: 10,603,314

PCT Information
PCT Filed	February 02, 2006	PCT Application Number:	PCT/US2006/003717
PCT Publication Date:	August 10, 2006	PCT Publication Number:	WO2006/084058

International Family Members for US Patent 10,603,314

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E504299
Australia	2006210572
Brazil	PI0606839
Canada	2596714
China	101155579
China	102886045
China	108421044